Dr Michael Johnson is a Consultant Neurologist at Imperial College Healthcare and Deputy Head of the Centre for Clinical Translation in the Division of Brain Sciences at Imperial College. His research involves the application of computational biology and genomics to discover new drug targets and therapies for diseases of the human brain. Dr Johnson leads a research group supported by three post-doctoral researchers, two PhD students and one research nurse. His research is funded by the MRC, UCB Pharma, the NIHR Biomedical Research Centres Scheme, the EU FP7 Framework and the Brain Tumour Research Campaign (BTRC). Funded by the Wellcome Trust, he coordinated the largest prospective epilepsy pharmacogenetic cohort worldwide. He is a Trustee of the BTRC (www.wayahead-btrc.org), a member of the International League Against Epilepsy (ILAE) Task Force on Pharmacogenetics, and the Epi4K, EpiPGx and EPITARGET international consortia in epilepsy. He is an academic advisor to the Commonwealth Scholarship Commission and a clinical advisor to the UK Parliamentary Health Ombudsman. His clinical activity is in general neurology and epilepsy with a particular interest in the autoimmune and tumour associated epilepsies. Dr Johnson is a core member of the neuro-oncology multidisciplinary team.
Fellow of the Royal College of Physicians (FRCP)
Fellow of the Royal Australasian College of Physicians (FRACP)
Fellow of the Royal Society of Medicine
Member of the Association of British Neurologists
Member of the British Medical Association
Member of International League Against Epilepsy